guselkumab (tremfya) Report issue

Biologics mAb Approved FDA First in Class Priority Review FDA

Active Ingredient History

NOW
  • Now
Guselkumab, sold under the brand name Tremfya, is a monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$2859.8956

United States

$7942.3100 - $10842.2800
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

cnto 1959 | ctno 1959 | guselkumab | tremfya

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue